Clinical trial · Interventional
Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast United States
NCT02867722CI-TRIAL-00049738DaylightPDTwithdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The PI decided to not proceed with the trial due to lack of funding.
Summary
Brief summary (as posted)
In this study, daylight PDT will be administered to interested patients at Dana-Farber/Brigham and Women's Cancer Center. Daylight PDT has been shown to be an effective and painless alternative to traditional PDT. Daylight PDT involves application of the photosensitizer in the physician's office followed by exposure to daylight.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Actinic Keratosis | — | UNRESOLVED | — |
| Non-melanoma Skin Cancer | Skin Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| aminolevulinic acid HCl | Drug | Aminolevulinic Acid | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Daylight PDT
- description
- Patients will receive daylight-PDT treatment (aminolevulinic acid)
- interventionNames
- Drug: aminolevulinic acid HCl
Primary outcomes (1)
- measure
- Number of patients with reduction in the number of actinic keratoses after daylight PDT treatment
- timeFrame
- 1 year and 5 years
Secondary outcomes (3)
- measure
- Number of non-melanoma skin cancers at 1- and 5-years compared to the number of skin
- timeFrame
- 1 year and 5 years
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients ≥ 18 years referred for the treatment of 5 or more visible or palpable actinic keratoses on one treatment area Exclusion Criteria: * Age less than 18 years of age. * Pregnant women. * Non-English speaking patients. * Treatment of actinic keratoses with other modalities including topical 5-fluorouracil, topical imiquimod, conventional PDT, alpha-hydroxy-acids, and glycolic acids within 2 months * Use of retinoids within 1 month * Use of the following medications: griseofulvin, thiazide diuretics, sulfonyureas, phenothiazines, sulfonamides, and tetracyclines * History of cutaneous photosensitivity, lupus, porphyrias, or any other photosensitizing condition
References
Publications (0)
Data not yet available
No reference posted for this study.